Cost Effectiveness of Pembrolizumab (Keytruda®) Versus Ipilimumab in Patients with Advanced Melanoma in the United States
May 1, 2016, 00:00
10.1016/j.jval.2016.03.1613
https://www.valueinhealthjournal.com/article/S1098-3015(16)01681-8/fulltext
Title :
Cost Effectiveness of Pembrolizumab (Keytruda®) Versus Ipilimumab in Patients with Advanced Melanoma in the United States
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(16)01681-8&doi=10.1016/j.jval.2016.03.1613
First page :
A154
Section Title :
Cancer - Cost Studies
Open access? :
No
Section Order :
337